RTTNews | Apr 27, 2021 08:09AM EDT

08:08 Tuesday, April 27, 2021 (RTTNews.com) - Aldeyra Therapeutics, Inc. (ALDX) reported positive top-line results from the phase 3 INVIGORATE clinical trial of 0.25% reproxalap ophthalmic solution, an investigational new drug, in patients with allergic conjunctivitis. The company said the clinical trial successfully achieved statistical significance for the primary endpoint and all secondary endpoints.

Aldeyra plans to meet with the FDA in the second half of 2021 to discuss the INVIGORATE results and the potential submission of a New Drug Application.

Shares of Aldeyra Therapeutics were up 25% in pre-market trade on Tuesday.

Read the original article on RTTNews ( https://www.rttnews.com/3188490/aldeyra-reports-positive-top-line-results-from-phase-3-invigorate-trial-quick-facts.aspx)

For comments and feedback: contact editorial@rttnews.com

Copyright(c) 2021 RTTNews.com All Rights Reserved